Stocks · News reference
Valion Bio Says AFRRI Under NIAID Contract To Begin Government-Funded Entolimod Safety Study This Week For Radiation-Induced GI Injury; Top-Line Therapeutic Data Expected In Early Fall
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 1:33 PM
- Checked
- Aug 12, 2026, 1:33 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Valion Bio Announces 1-For-25 Reverse Stock Split, Effective Aug. 31
Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company's issued and outstanding shares of
Read original at benzinga8-K filing — Valion Bio, Inc. (VBIO)
Filed: 2026-08-27 AccNo: 0001683168-26-006742 Size: 244 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarWhy Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Shares of Cadeler A/S (NYSE: CDLR) surged in pre-market trading after reporting strong financial results for the first half of 2026. Revenue and profit increased significantly, and full-year guidance was maintained. Other stocks also moved in pre-market trading.
Read original at benzinga